Department of Anesthesiology, Fujian Maternity and Child Health Hospital, Affiliated Hospital of Fujian Medical University, 18 Daoshan Road, Fuzhou, 350001, Fujian Province, China.
BMC Anesthesiol. 2021 Dec 1;21(1):299. doi: 10.1186/s12871-021-01525-0.
BACKGROUND: Propofol, a widely used sedative in endoscopic procedures, sometimes causes cardiopulmonary complications. Intravenous lidocaine can diminish visceral pain and decrease the dose of propofol. The purpose of this study was to assess the efficacy and safety of intravenous lidocaine in reducing propofol dosage during paediatric colonoscopy. METHODS: Forty children who underwent colonoscopy were divided into two groups. Lidocaine hydrochloride (1.5 mg/kg induction and 2 mg/kg/h maintenance) was given intravenously to the lidocaine group, and the same amount of saline was given to the control group after they received lidocaine induction. Propofol initial plasma concentration of 5 μg/mL was targeted, and the procedure was performed after the bispectral index value reached 55. The primary outcome was propofol requirement. RESULTS: The propofol requirement in the lidocaine group was decreased by 35.5% (128.6 ± 30.4 mg vs. 199.4 ± 57.6 mg; p < 0.001; 95%CI: - 100.60, - 41.02). The incidence of involuntary body movements was significantly lower in the lidocaine group (p = 0.028; OR = 0.17; 95%CI: 0.03, 0.92). The awakening time (p < 0.001; 95%CI: - 7.67, - 5.13) and recovery times (p < 0.001; 95%CI: - 7.45, - 4.35) were significantly lower in the lidocaine group. Pain was significantly less at 30 min and 60 min after the procedure in the lidocaine group (0 [0-4] vs. 3 [0-5], p < 0. 001; 0 [0-2] vs. 1 [0-3], p = 0.001). There was no difference in the incidence of bradycardia, hypotension, or hypoxia between the two groups. CONCLUSIONS: For colonoscopy procedures in paediatric patients, intravenous lidocaine reduces the amount of propofol needed, provides better sedation and postprocedural pain management, as well as a reduction in recovery time. TRIAL REGISTRATION: The trial was registered on November 6, 2020 at China Clinical Trials Registration Center ( www.chictr.org.cn ) ref.: ChiCTR 2,000,039,706.
背景:丙泊酚是一种在内镜检查中广泛使用的镇静剂,有时会引起心肺并发症。静脉内给予利多卡因可以减轻内脏疼痛并减少丙泊酚的剂量。本研究旨在评估静脉内利多卡因在减少小儿结肠镜检查中丙泊酚用量方面的疗效和安全性。
方法:40 名接受结肠镜检查的儿童被分为两组。利多卡因组静脉内给予盐酸利多卡因(诱导剂量 1.5mg/kg,维持剂量 2mg/kg/h),而对照组在接受诱导剂量后给予等量生理盐水。目标是丙泊酚初始血浆浓度为 5μg/mL,当双频谱指数值达到 55 后进行操作。主要结局是丙泊酚的需求。
结果:利多卡因组丙泊酚的需求量减少了 35.5%(128.6±30.4mg 与 199.4±57.6mg;p<0.001;95%CI:-100.60,-41.02)。利多卡因组无意识的身体运动发生率明显较低(p=0.028;OR=0.17;95%CI:0.03,0.92)。苏醒时间(p<0.001;95%CI:-7.67,-5.13)和恢复时间(p<0.001;95%CI:-7.45,-4.35)均明显缩短利多卡因组。术后 30 分钟和 60 分钟时,利多卡因组疼痛明显减轻(0[0-4]与 3[0-5],p<0.001;0[0-2]与 1[0-3],p=0.001)。两组间心动过缓、低血压或低氧血症的发生率无差异。
结论:对于小儿结肠镜检查,静脉内给予利多卡因可减少所需的丙泊酚剂量,提供更好的镇静和术后疼痛管理,并缩短恢复时间。
试验注册:该试验于 2020 年 11 月 6 日在中国临床试验注册中心(www.chictr.org.cn)注册,注册号为 ChiCTR2000039706。
Zhonghua Yi Xue Za Zhi. 2017-3-28